论文部分内容阅读
目的探讨人尿激肽原酶治疗急性脑梗死的临床疗效及对血清C-反应蛋白(CRP)水平的影响。方法 80例急性脑梗死随机分为治疗组和对照组,对照组给予常规基础治疗和个体化治疗,治疗组在对照组的基础上给予给予0.15PNA人尿激肽原酶治疗,连续治疗14d后评价临床疗效,测定治疗前后的血清CRP水平。结果治疗后,两组NIHSS评分显著下降,BI指数评分显著上升,与治疗前比较差异均有统计学意义(P﹤0.05),且治疗组与对照组比较差异均有统计学意义(P﹤0.05)。治疗组临床疗效总有效率为85.0%,对照组为42.5%,治疗组临床疗效总有效率显著高于对照组,相比较差异有统计学意义(P﹤0.05)。治疗后,两组血清CRP水平显著下降,与治疗前比较差异均有统计学意义(P﹤0.00),且治疗组与对照组比较差异有统计学意义(P﹤0.00)。结论尿激肽原酶能有效改善急性脑梗死患者的神经功能,减轻脑梗死所致脑损伤,提高患者生活质量。
Objective To investigate the clinical efficacy of human urokinase in the treatment of acute cerebral infarction and its effect on serum C-reactive protein (CRP) level. Methods 80 cases of acute cerebral infarction were randomly divided into treatment group and control group. The control group was given routine basic treatment and individualized treatment. The treatment group was given 0.15PNA human kallikrein treatment on the basis of the control group. After continuous treatment for 14 days Evaluation of clinical efficacy, determination of serum CRP levels before and after treatment. Results After treatment, the scores of NIHSS decreased significantly in both groups, and the scores of BI index increased significantly compared with those before treatment (P <0.05), and the differences between the two groups were statistically significant (P <0.05 ). The total effective rate was 85.0% in the treatment group and 42.5% in the control group. The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). After treatment, serum CRP level decreased significantly in both groups, with statistical significance (P <0.00), and the difference between the treatment group and the control group was statistically significant (P <0.00). Conclusions Urinary kallikrein can effectively improve the neurological function of patients with acute cerebral infarction, relieve brain injury induced by cerebral infarction and improve the quality of life of patients.